Diverticulitis Drugs Market

Segmentation by Drug Type {Antibiotics (Metronidazole, Amoxicillin, Moxifloxacin and Others), Dietary Fiber, and Others}; by Route of Administration (Oral, and Intravenous); by Distribution Channel (Online and Offline); and by End-User (Specialty Clinics, Hospitals, Research Centers, and Others) – Global Demand Analysis and Opportunity Outlook 2029

Buy Now
Report ID: 3054 | Published On: Feb 10, 2023
Request Free Sample Copy

Global Diverticulitis Drugs Market Regional Synopsis

On the basis of regional analysis, the global diverticulitis drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa region.

The market in the North America is anticipated to hold the largest market share over the forecast period on account of rising obese population, and availability of advanced treatment options. Additionally, the growing cases of various gastrointestinal diseases, including diverticulitis, is estimated to boost the market growth. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in the United States, about 58% of the individuals above 60 years of age have diverticulosis and about 5% of people with diverticulosis tends to develop diverticulitis. According to another report by the NIDDK, around 200,000 individuals are hospitalized for diverticulitis each year in the United States.

The market in the Asia Pacific is anticipated to grow at the highest CAGR over the forecast period owing to the growing number of patients, rising awareness among the individuals regarding health, availability of new treatment methods, improvement in the standard of living, and rapidly improving health care infrastructure.


The global diverticulitis drugs market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis.
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis.
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis.
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis.

Get more information on this report: Request Sample PDF

Major Macro-Economic Indicators Impacting the Market Growth


According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Get more information on this report: Request Sample PDF

Top Featured Companies Dominating the Market

    • Emmaus Life Sciences, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Synergy Pharma
    • Abbott Laboratories
    • GlaxoSmithKline plc
    •  Ardelyx, Inc.
    • Gilead Sciences, Inc.
    • Trumac Healthcare
    • Pfizer Inc.
    • Hikma Pharmaceuticals PLC
    • Takeda Pharmaceutical Company Limited


In The News

  • April 2022: IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.
  • March 2022: Indegene a provider of technology-driven healthcare solutions, & meta Me Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).

Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the diverticulitis drugs market?

Ans: Growing prevalence of gastrointestinal problems backed by unhealthy diet, lifestyle diseases, and obesity, is the major factor driving the market growth.

2) What would be the CAGR of diverticulitis drugs market over the forecast period?

Ans: The market is anticipated to attain a significant CAGR over the forecast period, i.e., 2021-2029.

3) What are the challenges affecting the diverticulitis drugs market growth?

Ans: Lack of awareness about the seriousness of this problem among people is the major factor estimated to hamper the market growth.

4) Which region will provide more business opportunities for growth of diverticulitis drugs market in future?

Ans: The market in North America will provide the highest growth opportunities for the market during the forecast period on the back of efficient healthcare sector and growing medical R&D activities.

5) Who are the major players dominating the diverticulitis drugs market?

Ans: The major players in the market are Abbott Laboratories, Pfizer Inc., GlaxoSmithKline plc, Ardelyx, Inc., Gilead Sciences, Inc., Trumac Healthcare, Hikma Pharmaceuticals PLC, Takeda Pharmaceutical Company Limited and others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the global diverticulitis drugs market?

Ans: The market is segmented by drug type, route of administration, distribution channel, end-user, and by region.

8) Which segment captures the largest market size in the end-user segment in the diverticulitis drugs market?

Ans: The hospital segment is anticipated to hold the largest market size during the forecast period on the back of various complications in this disease, which might require immediate attention.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Request Research Report Sample